Eupraxia Pharmaceuticals, Inc. EPRX 深 沪
交易中 10-08 11:24:59 美东时间
7.45
-0.330
-4.24%
华盛通- 最 高7.75
- 今 开7.69
- 成交量 16.34万股
- 最 低 7.34
- 昨 收 7.78
- 总市值 4.92亿
- 52周最高 9.32
- 市盈率 静 --
- 换手率 0.25%
- 52周最低 5.25
- 委 比 42.42%
- 总股本 6607.34万
- 历史最高 9.32
- 量 比 0.33
- 振 幅 5.27%
- 历史最低 2.20
- 每 手 1
- 风险率 0.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅1654.39%！Ascendiant Capital上调NRX Pharmaceuticals(NRXP)目标价至50美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从49美元升至50美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从24美元升至25美元
10-02 08:33
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
Wedbush Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17
Wedbush analyst Martin Fan initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.
09-24 20:38
美股牛股 | Belite Bio飙升13.2%，获大行看高至303美元，潜在升幅约77%；存储、光通信板块逆势狂涨！Aehr Test Systems劲升13%，闪迪升近12%
Belite Bio飙升13.2%，获大行看高至303美元，潜在升幅约77%；存储、光通信板块逆势狂涨！Aehr Test Systems劲升13%，闪迪升近12%>>
09-05 06:25
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 250 points on Wednesday. Shares of Sirius XM Holdings Inc (NASDAQ:SIRI) rose sharply during Wednesday’s session after Deutsche Bank upgraded the stock from Hold to Buy and raised its price target from $31 to $45. Sirius XM share...
09-02 22:26
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
Eupraxia Pharmaceuticals Inc. announced positive results from the RESOLVE study, showing EP-104GI significantly reduces symptoms of odynophagia (pain swallowing) and dysphagia (difficulty swallowing) in EoE patients. Moderate to severe odynophagia dropped from 62% at baseline to 25% at 24-52 weeks, with no severe cases reported post-treatment. Similarly, moderate to severe dysphagia decreased from 77% to 25%. EP-104GI demonstrated good tolerabili...
08-13 12:00
Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 11.54 percent increase over losses of $(0.26) per share from the same period last year.
08-12 05:32
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Eupraxia Pharmaceuticals Inc. announced its Q2 2026 financial results, reporting a net loss of $14.5 million, up from $8.7 million in Q2 2025, due to increased R&D and general expenses. The company highlighted positive data from its EP-104GI Phase 1b/2a trial in Eosinophilic Esophagitis (EoE), showing improvement in fibrosis and inflammation. Recent operational highlights include leadership appointments and the expansion of its EP-104GI target in...
08-11 21:21
美股大行评级 | 潜在涨幅90.66%！Tango Therapeutics获杰富瑞升目标价至60美元，上调至"买入"评级
今日重点评级关注：杰富瑞：上调Tango Therapeutics评级至"买入"，目标价从27美元升至60美元；Susquehanna：维持安森美半导体"积极"评级，目标价从120美元升至140美元
06-29 15:49
Oppenheimer Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17
Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.
06-26 21:12
